All trans 1-(3-arylacryloyl)-3,5-bis (pyridin-4-ylmethylene)piperidin-4-ones as curcumin-inspired antineoplastics

European Journal of Medicinal Chemistry

Volumn 87, Issue , 2014, Pages 461-470

  Paul, Nawal K ^a   Jha, Mamta ^a   Bhullar, Khushwant S ^b   Rupasinghe, H P Vasantha ^b   Balzarini, Jan ^c   Jha, Amitabh ^a  

^a ACADIA UNIVERSITY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Anti oxidant; Curcumin; Cytostatic activity; Michael acceptor; QSAR; Topoisomerase II inhibitors

Indexed keywords

(3E,5E) 1 ((E) 3 (3,4 DICHLOROPHENYL)ACRYLOYL) 3,5 BIS(PYRIDIN 4 YLMETHYLENE)PIPERIDIN 4 ONE; (3E,5E) 1 ((E) 3 (3,4 DIMETHOXYPHENYL)ACRYLOYL) 3,5 BIS(PYRIDIN 4 YLMETHYLENE)PIPERIDIN 4 ONE; (3E,5E) 1 ((E) 3 (3,4,5 TRIMETHOXYPHENYL)ACRYLOYL) 3,5 BIS(PYRIDIN 4 YLMETHYLENE)PIPERIDIN 4 ONE; (3E,5E) 1 ((E) 3 (4 CHLOROPHENYL)ACRYLOYL) 3,5 BIS(PYRIDIN 4 YLMETHYLENE)PIPERIDIN 4 ONE; (3E,5E) 1 ((E) 3 (4 METHOXYPHENYL)ACRYLOYL) 3,5 BIS(PYRIDIN 4 YLMETHYLENE)PIPERIDIN 4 ONE; (3E,5E) 1 ((E) 3 (4 METHYLPHENYL)ACRYLOYL) 3,5 BIS(PYRIDIN 4 YLMETHYLENE)PIPERIDIN 4 ONE; (3E,5E) 1 ((E) 3 (4 NITROPHENYL)ACRYLOYL) 3,5 BIS(PYRIDIN 4 YLMETHYLENE)PIPERIDIN 4 ONE; (3E,5E) 1 ((E) 3 (BENZO[D][1,3]DIOXOL 5 YL)ACRYLOYL) 3,5 BIS(PYRIDIN 4 YLMETHYLENE)PIPERIDIN 4 ONE; (3E,5E) 1 ((E) 3 (FURAN 2 YL)ACRYLOYL) 3,5 BIS(PYRIDIN 4 YLMETHYLENE)PIPERIDIN 4 ONE; (3E,5E) 1 ((E) 3 PHENYLACRYLOYL) 3,5 BIS(PYRIDIN 4 YLMETHYLENE)PIPERIDIN 4 ONE; (3E,5E) 1 ACRYLOYL 3,5 BIS(PYRIDIN 4 YLMETHYLENE)PIPERIDIN 4 ONE; (3E,5E) 3,5 BIS(PYRIDIN 4 YLMETHYLENE)PIPERIDIN 4 ONE TRIHYDROCHLORIDE; ANTINEOPLASTIC AGENT; ANTIOXIDANT; CURCUMIN; MELPHALAN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; PHYSICAL CHEMISTRY; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

EID: 84949116413     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.09.090     Document Type: Article

References (49)

1. S.C. Gupta, G. Kismali, B.B. Aggarwal, Curcumin, a component of turmeric: from farm to pharmacy, BioFactors 39 (2013) 2-13.
2. N. Samaan, Q. Zhong, J. Fernandez, G. Chen, A.M. Hussain, S. Zheng, G. Wang, Q.-H. Chen, Design, synthesis, and evaluation of novel heteroaromatic analogs of curcumin as anti-cancer agents, Eur. J. Med. Chem. 75 (2014) 123-131.
3. A. Brown, Q. Shi, T.W. Moore, Y. Yoon, A. Prussia, C. Maddox, D.C. Liotta, H. Shim, J.P. Snyder, Monocarbonyl curcumin analogues: heterocyclic pleiotropic kinase inhibitors that mediate anticancer properties, J. Med. Chem. 56 (2013) 3456-3466.
4. J.R. Dimmock, A. Jha, G.A. Zello, J.W. Quail, E.O. Oloo, K.H. Nienaber, E.S. Kowalczyk, T.M. Allen, C.L. Santos, E. De Clercq, J. Balzarini, E.K. Manavathu, J.P. Stables, Cytotoxic N-[4-(3-aryl-3-oxo-1-propenyl)phenylcarbonyl]-3,5-bis(phenylmethylene)-4-piperidones and related compounds, Eur. J. Med. Chem. 37 (2002) 961-972.
5. J.R. Dimmock, A. Jha, G.A. Zello, R.K. Sharma, A. Shrivastav, P. Selvakumar, T.M. Allen, C.L. Santos, J. Balzarini, E. De Clercq, E.K. Manavathu, J.P. Stables, 3,5-Bis(Phenylmethylene)-1-(N-arylmaleamoyl)-4-piperidones: a novel group of cytotoxic agents, J. Enzyme Inhib. Med. Chem. 18 (2003) 325-332.
6. A. Jha, J.R. Dimmock, Syntheses of 4-(3,5-Bisphenylmethylene-4-oxo-piperidin-1-yl)-4-oxo-but-2 Z-enoic acid arylamides as candidate cytotoxic Agents, Synth. Commun. 33 (2003) 1211-1223.
7. A. Jha, C. Mukherjee, A.K. Prasad, V.S. Parmar, E.D. Clercq, J. Balzarini, J.P. Stables, E.K. Manavathu, A. Shrivastav, R.K. Sharma, K.H. Nienaber, G.A. Zello, J.R. Dimmock, E, E,E-1-(4-Arylamino-4-oxo-2-butenoyl)-3,5-bis(arylidene)-4-piperidones: a topographical study of some novel potent cytotoxins, Bioorg. Med. Chem. 15 (2007) 5854-5865.
8. K. Bhullar, A. Jha, D. Youssef, H.P.V. Rupasinghe, Curcumin and its carbocyclic analogs: structure-activity in relation to antioxidant and selected biological properties, Molecules 18 (2013) 5389-5404.
9. A. Jha, J. Zhao, T. Stanley Cameron, E. De Clercq, J. Balzarini, E.K. Manavathu, J.P. Stables, Design, synthesis and biological evaluation of novel curcumin analogues as anti-neoplastic agents, Lett. Drug Des. Discov. 3 (2006) 304-310.
10. C.E. Nichols, D. Youssef, R.G. Harris, A. Jha, Microwave-assisted synthesis of curcumin analogs, Arkivoc 13 (2006) 64-72.
11. D. Youssef, C.E. Nichols, T.S. Cameron, J. Balzarini, E. De Clercq, A. Jha, Design, synthesis, and cytostatic activity of novel cyclic curcumin analogues, Bioorg. Med. Chem. Lett. 17 (2007) 5624-5629.
12. B. Mutus, J.D. Wagner, C.J. Talpas, J.R. Dimmock, O.A. Phillips, R.S. Reid, 1-p-Chlorophenyl-4,4-dimethyl-5-diethylamino-1-penten-3-one hydrobromide, a sulfhydryl-specific compound which reacts irreversibly with protein thiols but reversibly with small molecular weight thiols, Anal. Biochem. 177 (1989) 237-243.
13. L. Swift, R. Golsteyn, Genotoxic anti-Cancer agents and their relationship to DNA damage, mitosis, and checkpoint adaptation in proliferating cancer cells, Int. J. Mol. Sci. 15 (2014) 3403-3431.
14. J.R. Dimmock, V.K. Arora, S.L. Wonko, N.W. Hamon, J.W. Quail, Z. Jia, R.C. Warrington, W.D. Fang, J.S. Lee, 3,5-Bis-benzylidene-4-piperidones and related compounds with high activity towards P388 leukemia cells, Drug Des. Deliv. 6 (1990) 183-194.
15. J.R. Dimmock, V.K. Arora, J.W. Quail, U. Pugazhenthi, T.M. Allen, G.Y. Kao, E. De Clercq, Cytotoxic evaluation of some 3,5-diarylidene-4-piperidones and various related quaternary ammonium compounds and analogs, J. Pharm. Sci. 83 (1994) 1124-1130.
16. A. Jha, K.M. Duffield, 3, 5-Bis (arylmethylene)-4-piperidone derivatives as novel anticancer agents, Indian J. Chem. Sect. B Org. Chem. Incl. Med. Chem. 45 (2006) 2313-2320.
17. J.R. Dimmock, M.P. Padmanilayam, R.N. Puthucode, A.J. Nazarali, N.L. Motaganahalli, G.A. Zello, J.W. Quail, E.O. Oloo, H.-B. Kraatz, J.S. Prisciak, T.M. Allen, C.L. Santos, J. Balzarini, E. De Clercq, E.K. Manavathu, A conformational and structure-activity relationship study of cytotoxic 3,5-Bis(arylidene)-4-piperidones and related n-acryloyl analogues, J. Med. Chem. 44 (2001) 586-593.
18. J.R. Dimmock, A. Jha, G.A. Zello, T.M. Allen, C.L. Santos, J. Balzarini, E. De Clercq, E.K. Manavathu, J.P. Stables, Cytotoxic 4-aminochalcones and related compounds, Pharmazie-An Int. J. Pharm. Sci. 58 (2003) 227-232.
19. J.R. Dimmock, A. Jha, P. Kumar, G.A. Zello, J.W. Quail, E.O. Oloo, J.J. Oucharek, M.K. Pasha, D. Seitz, R.K. Sharma, T.M. Allen, C.L. Santos, E.K. Manavathu, E. De Clercq, J. Balzarini, J.P. Stables, Cytotoxic 1,4-bis(2-oxo-1-cycloalkylmethylene)benzenes and related compounds, Eur. J. Med. Chem. 37 (2002) 35-44.
20. A. Jha, C. Mukherjee, A.J. Rolle, E. De Clercq, J. Balzarini, J.P. Stables, Cytostatic activity of novel 40-aminochalcone-based imides, Bioorg. Med. Chem. Lett. 17 (2007) 4545-4550.
21. V. Parmar, S. Jain, K. Bisht, N.K. Sharma, S. Gupta, A.K. Prasad, A. Jha, S. Malhotra, S.K. Sharma, M. Bracke, Synthesis and anti-invasive activity of novel 1, 3-diarylpropenones, Indian J. Chem. Sect. B Org. Chem. Incl. Med. Chem. (1999) 628-643.
22. D. Youssef, E. Potter, M. Jha, E. De Clercq, J. Balzarini, J.P. Stables, A. Jha, Design, synthesis and bioevaluation of novel maleamic amino acid ester conjugates of 3,5-bisarylmethylene-4-piperidones as cytostatic agents, Bioorg. Med. Chem. Lett. 19 (2009) 6364-6367.
23. D.T. Davies, Aromatic Heterocyclic Chemistry, Oxford University Press, 1992.
24. G.S. Paulekuhn, J.B. Dressman, C. Saal, Trends in active pharmaceutical ingredient salt selection based on analysis of the orange book database, J. Med. Chem. 50 (2007) 6665-6672.
25. A.K. McClendon, N. Osheroff, DNA topoisomerase II, genotoxicity, and cancer, Mutat. Res. 623 (2007) 83-97.
26. J.E. Deweese, N. Osheroff, The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing, Nucleic Acids Res. 37 (2009) 738-748.
27. D.A. Burden, N. Osheroff, Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme, BBA-Gene Struc. Expr. 1400 (1998) 139-154.
28. J.C. Wang, Cellular roles of DNA topoisomerases: a molecular perspective, Nat. Rev. Mol. Cell Biol. 3 (2002) 430-440.
29. J.J. Champoux, DNA topoisomerases: structure, function, and mechanism, Annu. Rev. Biochem. 70 (2001) 369-413.
30. P. Chene, J. Rudloff, J. Schoepfer, P. Furet, P. Meier, Z. Qian, J.M. Schlaeppi, R. Schmitz, T. Radimerski, Catalytic inhibition of topoisomerase II by a novel rationally designed ATP-competitive purine analogue, BMC Chem. Biol. 9 (2009) 1.
31. A. Jha, N.K. Paul, S. Trikha, T.S. Cameron, Novel synthesis of 2-naphthol Mannich bases and their NMR behaviour, Can. J. Chem. 84 (2006) 843-853.
32. P.-J.J. Huang, D. Youssef, T.S. Cameron, A. Jha, Microwave-assisted synthesis of novel 2-naphthol bis-Mannich bases, Arkivoc 16 (2008) 165-177.
33. D. Mathur, A.K. Prasad, T.S. Cameron, A. Jha, Novel approach to 3,3-dimethyl-4-morpholino-3,4-dihydrocoumarins via hetero-Diels-Alder reaction, Tetrahedron 70 (2014) 5608-5618.
34. J. Balzarini, E. De Clercq, M.P. Mertes, D. Shugar, P.F. Torrence, 5-Substituted 20-deoxyuridines: correlation between inhibition of tumor cell growth and inhibition of thymidine kinase and thymidylate synthetase, Biochem. Pharmacol. 31 (1982) 3673-3682.
35. J.R. Dimmock, P. Kumar, A.J. Nazarali, N.L. Motaganahalli, T.P. Kowalchuk, M.A. Beazely, J. Wilson Quail, E.O. Oloo, T.M. Allen, J. Szydlowski, E. DeClercq, J. Balzarini, Cytotoxic 2,6-bis(arylidene)cyclohexanones and related compounds, Eur. J. Med. Chem. 35 (2000) 967-977.
36. M.R. Boyd, K.D. Paull, Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen, Drug Dev. Res. 34 (1995) 91-109.
37. A.M. Whittle, S. Feyler, D.T. Bowen, Durable second complete remissions with oral melphalan in hypocellular Acute Myeloid Leukemia and Refractory Anemia with Excess Blast with normal karyotype relapsing after intensive chemotherapy, Leuk. Res. Rep. 2 (2013) 9-11.
38. A.K. Larsen, A.E. Escargueil, A. Skladanowski, Catalytic topoisomerase II inhibitors in cancer therapy, Pharmacol. Ther. 99 (2003) 167-181.
39. S. Gafner, S.-K. Lee, M. Cuendet, S. Barthelemy, L. Vergnes, S. Labidalle, R.G. Mehta, C.W. Boone, J.M. Pezzuto, Biologic evaluation of curcumin and structural derivatives in cancer chemoprevention model systems, Phytochemistry 65 (2004) 2849-2859.
40. B.K. Adams, E.M. Ferstl, M.C. Davis, M. Herold, S. Kurtkaya, R.F. Camalier, M.G. Hollingshead, G. Kaur, E.A. Sausville, F.R. Rickles, J.P. Snyder, D.C. Liotta, M. Shoji, Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents, Bioorg. Med. Chem. 12 (2004) 3871-3883.
41. L.J. Marnett, Oxyradicals and DNA damage, Carcinogenesis 21 (2000) 361-370.
42. J.A. Swenberg, K. Lu, B.C. Moeller, L. Gao, P.B. Upton, J. Nakamura, T.B. Starr, Endogenous versus exogenous DNA adducts: their role in carcinogenesis, epidemiology, and risk assessment, Toxicol. Sci. 120 (2011) S130-S145.
43. H. Wang, J.A. Joseph, Quantifying cellular oxidative stress by dichlorofluorescein assay using microplate reader, Free Radic. Biol. Med. 27 (1999) 612-616.
44. V. Fuchs-Tarlovsky, Role of antioxidants in cancer therapy, Nutrition 29 (2013) 15-21.
45. J.P. Stables, H.J. Kupferberg, The NIH Anticonvulsant Drug Development (ADD) Program: Preclinical Anticonvulsant, 1997.
46. Chargeb, partition coefficients (LogP) and molar refractivity (MRmol) were calculated by Chem3D® computer program (version 8.0) after energy minimization of the molecules using MOPAC. Chem3D® is obtainable from Cambridge Soft Corporation, Cambridge, MA, USA.
47. C. Hansch, A. Leo, D. Hoekman, S.R. Heller, Exploring Qsar, American Chemical Society, Washington, DC, 1995.
48. Minitab® Release 14 obtained from Minitab Inc., Quality Plaza, 1829 Pine Hall Road, State College, PA 16801-3008, USA.
49. N.W. Dunham, T.S. Miya, A note on a simple apparatus for detecting neurological deficit in rats and mice, J. Am. Pharm. Assoc. 46 (1957) 208-209.